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Abstract. We report a novel BRCA1 germline 4156delAA 
mutation detected in a 41-year-old woman with breast and 
ovarian cancer. Genomic DNA was obtained from periph-
eral blood. Standard polymerase chain reactions and direct 
sequencing were performed. This mutation originates a 
premature stop at codon 1354 of BRCA1 protein and has 
not been documented in any published report to the best of 
our knowledge. The mutation was not observed in any other 
family studied. Since this novel mutation was associated 
with both breast and ovarian cancer, the genotype-phenotype 
correlation was investigated in a patient base of 30 families.
Introduction
Mutations in the breast and ovarian cancer susceptibility 
genes BRCA1 and BRCA2 are found in a high proportion of 
multiple-case families with breast cancer, particularly if one 
or more cases of patients with ovarian cancer are included. 
More than 400 distinct cancer-associated BRCA1 and BRCA2 
mutations have been reported according to the Breast Cancer 
Information Core (BIC) database (http://www.nchgr.nih.gov/
bic), a widespread international reference for information 
regarding mutations and polymorphisms in the two genes. 
Effective screening for cancer-associated mutations in BRCA1 
and BRCA2 may aid in elucidating the molecular mechanisms 
of carcinogenesis, and is crucial to risk assessment and cancer 
treatment.
Materials and methods
A Spanish 41-year-old non-Ashkenazi female patient was 
diagnosed and treated for breast and ovarian cancer at another 
center. Genomic DNA was obtained from peripheral blood 
and automatically extracted (MagNΑ Pure, Roche, Barcelona, 
Spain). Standard polymerase chain reactions were performed 
using AmpliTaq Gold polymerase from Perkin-Elmer 
(Waltham, MA, USA). Direct sequencing of the complete 
BRCA1 was performed to the standard method on an auto-
mated sequencer ABI PRISM® 377 Genetic Analyzer (Applied 
Biosystems, Carlsbad, CA, USA) and genetic variants were 
detected by comparison with a consensus wild-type sequence 
(GenBank NM_007294.2). Any mutation found was confirmed 
by repeated analysis, including reverse-primer sequencing 
of the suspicious exon. A group of 175 patients with a family 
history of ovarian and breast cancer were used to screen for the 
mutation found.
Finally, we analyzed the genotype-phenotype correlation 
in 30 families at our center. The subjects were eligible for 
inclusion into the study if they tested positive for a patho-
logical BRCA1 or BRCA2 truncation mutation. Families with 
missense mutations that would not necessarily be expected 
to have the same phenotypic effect as would be produced by 
protein-truncating mutations at the same position in the gene 
were excluded.
In accordance with normal clinical practice all of the 
patients included in the study provided written informed 
consent prior to blood sample extraction and we followed the 
Good Clinical Practice guidelines previously approved by our 
Ethics Committee.
Results and Discussion
A 4156delAA frameshift mutation was found in exon 11 of 
BRCA1, yet to be reported in the BIC database (Fig. 1A). 
Frequent truncations found in the Spanish population are 
187delAG and 5385insC in BRCA1 and 3036del4, 3492insT, 
5374del4, 9254delTCAT and 9538del2 in BRCA2 (1,2). 
Geographical variations in the mutations distribution may 
be due to founder effects. The mutation in 175 families 
from various Spanish regions was analyzed with no positive 
results. Further investigations in low-represented Spanish 
areas may facilitate a description of genetic influences and 
associated phenotype features. The focus of this investigation 
was on two main areas: i) genotype-phenotype correlation 
and ii) the functional consequences of the BRCA1-truncated 
protein. Since the 4156delAA frameshift mutation is associ-
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ated with breast and ovarian cancer in the same patient, we 
investigated the genotype-phenotype correlation in the muta-
tions found in our sample.
In their study (3), Gayther et al studied groups of 32 and 25 
families, providing evidence for a genotype-phenotype correla-
tion in BRCA1 and BRCA2, respectively. These authors found 
that a linear trend model for the breast and ovarian cancer ratio 
was less satisfactory than a model dividing BRCA1/BRCA2 
genes into discrete regions, and defined an ovarian cancer 
cluster region (OCCR) in BRCA2 (3,4). Thompson and Easton 
(on behalf of the Breast Cancer Linkage Consortium) studied 
BRCA1 and BRCA2 in 356 and 164 families, respectively, and 
proposed a division of BRCA1 into three regions (of roughly 
equal size), with different associated risks showing an almost 
1:1 ratio (breast and ovarian) in the center, and significantly 
higher risk for breast cancer in the 3' and 5' regions (5,6). Using 
the inclusion criteria indicated above, we studied the genotype-
phenotype correlation in a total of 30 families. The mutation 
spectrum constituted 16 frameshift deletions or insertions, two 
nonsense mutations, two missense mutations and one mutation 
affecting splicing [all mutations have been described in the 
BIC database or were recently published (7-9)]. The distribution 
of the mutations found and correlation with the phenotype are 
shown in Fig. 1B. Despite the limited number of families and 
mutations, our frequencies were in agreement with the expected 
frequencies proposed by the extensive study of Thompson and 
Easton (5,6). The studies indicate that the novel 4156delAA 
mutation found in BRCA1 is likely to exhibit a 1.1:1 associated 
risk for breast and ovarian cancers.
 We have sought bibliographical information to further 
clarify the functional consequences of the BRCA1-truncated 
protein in order to gain a better understanding of biological 
mechanisms that may be responsible for the breast and ovarian 
cancer-risk variation among the different BRCA1 and BRCA2 
gene regions. Cancer risk patterns are similar in the two genes, 
with the OCCR region in BRCA2 and a central BRCA1 region 
with a higher risk of ovarian cancer (Fig. 1B). Previously, the 
homologous recombination (HR) was found to be dependent 
on the interaction between BRCA1 and BRCA2 (through the 
mediator protein PALB2), which is required for the recruit-
ment of RAD51. The OCCR region coincides with the 8 BRC 
repeat motifs that modulate the DNA binding of RAD51. 
Additionally, BRCT domains of BRCA1 are required for the 
interaction and recruitment of BRCA2/RAD51 to the damage 
Figure 1. (A) Direct sequencing of the BRCA1 exon 11. Arrow indicates the 4156delAA mutation. (B) Location of germline mutations in 30 families, either in 
BRCA1 or BRCA2. The BrC:OvC indicates the risk ratio of breast:ovarian cancers based on the studies of Thompson and Easton (5,6).
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sites for execution of the HR-DNA repair function (10). 
In this context, the 4156delAA frameshift mutation detected 
originates a premature stop at codon 1354, leading to a trun-
cated BRCA1 protein lacking the tandem BRCT C-terminal 
domains. Although it is possible that the positions of the 
risk-region boundaries relative to the RAD51-related domain 
are merely coincidental, it could be argued that the BRCA1 
and BRCA2 proteins truncated midway in the RAD51-related 
domain behave differently from other truncated proteins outside 
this domain, leading to a higher ovarian cancer risk. On the 
other hand, another potential biological scenario is one in 
which the existence of in-frame alternative splicing of the 
BRCA proteins is assumed by skipping the RAD51-related 
domain, but retaining a certain degree of BRCA functionality 
(11). If these isoforms were more frequent in breast epithelial 
tissue than in ovarian epithelial tissue then the partial rescue 
and, thus, the reduced penetrance would be evident only in 
breast cancer. More detailed functional and population studies 
are required to clarify these hypotheses.
Finally, a ‘BRCAness’ syndrome in ovarian cancer has 
been associated with serous histology, longer treatment-free 
interval between relapses, improved overall survival and high 
response rates to first and subsequent lines of platinum-based 
treatment (12). BRCA1 is involved in the nucleotide excision 
repair of DNA adducts, since it has been reported that BRCA1 
promotes the assembly of RAD51 after treatment with cisplat-
inum and that BRCA1-defective cells down-regulate ERCC1 
(13,14). Platinum-based compounds have not been included 
in conventional chemotherapy regimens for breast cancer. 
However, recent clinical studies, as well as potential molecular 
mechanisms, may indicate a rationale supporting the use of 
these compounds against hereditary and triple-negative pheno-
type breast cancer, particularly in the context of breast and 
ovarian cancer in the same patient.
In conclusion, the BRCAs genotype appears to have a 
significant impact on the molecular phenotype as well as 
on drug sensitivity. Although differences in risks are not 
currently sufficient to justify different clinical management 
according to the position of the mutation, it may prove useful 
for the provision of a more realistic assessment of the risk of 
breast and ovarian cancer in mutation carriers. Further large 
population-based studies of genotype-phenotype correlations 
and treatment outcome may improve the management of 
patients undergoing genetic testing. Therapeutic strategies 
benefiting from genetic scenarios provide a framework for 
individualized cancer treatments.
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